Editor's note

This ExpertREACT article was originally published on 30 April 2009. Epidemiological data and technology assessments described reflect the state of knowledge at that date.

A new pandemic threat emerges

On 17 April 2009, a CDC MMWR dispatch described two cases of febrile respiratory illness in California children involving an influenza virus substantially different from current human H1N1 viruses. By 29 April, the US CDC had recorded 91 US cases and one death, while Mexico reported 26 confirmed human cases including seven deaths. Seven additional countries - Austria, Canada, Germany, Israel, New Zealand, Spain and the UK - had confirmed H1N1 cases. The WHO rapidly elevated its pandemic alert level from Phase 3 to Phase 4, then Phase 5. The novel H1N1 virus was susceptible to oseltamivir (Tamiflu) and zanamivir (Relenza), which provided some immediate therapeutic option but was not a substitute for a protective vaccine.

Comparing H1N1 with H5N1 avian influenza highlighted important differences: H5N1 had accumulated only 421 cases and 257 deaths over multiple years with no confirmed sustained human-to-human transmission, while H1N1 demonstrated efficient human transmission from the outset. Against seasonal influenza, H1N1 appeared relatively mild in terms of early case severity - but its spread to healthcare workers and younger healthy adults rather than predominantly the elderly was a concerning epidemiological signal that it was behaving differently from typical seasonal strains.

Countries with confirmed H1N1 cases (April 30 2009)
8
US (91 cases), Mexico (26 confirmed), Canada, Germany, Austria, Israel, New Zealand, Spain and UK within days of first CDC identification

The technology imperative

VacZine Analytics argued that H1N1 had exposed the inherent limitations of global influenza vaccine manufacturing, which was overwhelmingly dependent on egg-based technology requiring months of lead time and constrained by egg supply. Cell-culture based manufacturing - already approved for products such as Fluvirin - and recombinant approaches offered faster scale-up potential but remained at limited capacity globally. The article called for H1N1 to be the catalyst for a genuine step-change in public and private investment in next-generation influenza manufacturing technologies, so that future pandemic vaccine responses could be mounted in weeks rather than months.